Last updated: 2026-09-16 09:45:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Champions Oncology, Inc. (CSBR) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $4.77, with a market capitalisation of $68.48M and a P/E ratio of 22.49. Over the past 52 weeks, its price has ranged from $4.64 to $8.31. This page covers its latest market performance, valuation, price trends and company information.
$68.48M | |
$4.87 | |
$17.90 | |
$1.11 | |
$4.77 | |
1.00 | |
9.63K | |
22.49 | |
$8.31 | |
$4.64 | |
-- | |
-- |
Champions Oncology, Inc. (CSBR) is trading at $4.77 in pre-market trading as of 2026-09-16 08:42:00, up 0.02% ($0.00) from the previous close of $4.77
Pre-market trading shows how investors are pricing CSBR before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Champions Oncology, Inc. (CSBR) moved from $5.22 to $4.77, representing a decline of 8.60% ($0.45).
The stock traded between $4.64 and $5.41 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 15.96 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 3.6%
CSBR is currently trading at $4.77, placing it 3.6% of the way from its 52-week low of $4.64 to its 52-week high of $8.31. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 214 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Champions Oncology, Inc. (CSBR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.